2024 ARCHIVES
Wednesday, March 27
Registration Open2:00 pm
Chairperson's Remarks
Douglas Flora, MD, Executive Medical Director, Oncology Services, St. Elizabeth Healthcare; Editor-in-Chief, AI in Precision Oncology Journal
John Mattison, MD, UCSD Scholar in Residence, Responsible AI and Advanced Technologies, Chief Medical Information Officer, Arsenal Capital Partners
Digital Twins and Optimal Treatment Development
Eric Stahlberg, PhD, Director, Cancer Data Science Initiatives, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Rockville, Maryland, USA
The recent advances in AI have accelerated interest in the use of digital twins and virtual models in medicine. The presentation will provide an overview of biomedical digital twins and how AI is impacting the development of precision medicine digital twins. The presentation will provide a glimpse into the future where diagnostics, virtual models, and AI algorithms converge to provide new avenues for optimal treatment in precision medicine.
Sanjay Juneja, MD, Hematologist & Medical Oncologist, Mary Bird Perkins Cancer Center
Refreshment Break in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)3:35 pm
Innovation in AI for Precision Oncology: Commercialization and Implementation Strategies
Application of AI in oncology has the potential to revolutionize cancer care, from early detection to precision medicine. The expert panel will discuss emerging opportunities for investment, innovation, and commercialization of AI-enabled technologies and solutions for precision oncology.
Oscar Puig, PhD, Vice President, Translational Medicine & Diagnostics, Nucleai
Ben Glass, Vice President, Product & Translational Research, PathAI
Arturo Loaiza-Bonilla, MD, Co-Founder & CMO, Massive Bio, Inc.
Close of Day5:15 pm
Thursday, March 28
Morning Coffee8:00 am
Stephen T. C. Wong, PhD, Chair & Professor, Houston Methodist Hospital and Weill Cornell Medical College
Delivering AI Solutions Effectively and Responsibly
Sonya Makhni, MD, Medical Director, Mayo Clinic Platform
Once an AI model is developed, it is only a fraction of the way to impacting outcomes. The model must seamlessly integrate into an extremely complex and nuanced health care system, where heterogeneous clinical workflows can challenge the success of any given AI model. Innovators, clinicians, and health systems must learn how to safely deploy solutions. In order to accomplish this, however, a novel approach to solution classification, clinical risk assessment, solution evaluation, quality management, monitoring, and bias assessment must be developed and applied in practice. Then, AI systems may be more effectively deployed within workflows and create real, sustainable value and impact health outcomes.
Deep Reinforcement Learning for Cost-Effective Medical Diagnosis
Yuan Luo, PhD, Chief AI Officer & Associate Professor, Northwestern University Feinberg School of Medicine
We apply reinforcement learning (RL) to optimize sequential lab test panel selection for cost-effective and accurate diagnosis in cases where clinical data is imbalanced. We introduce a reward shaping approach to find Pareto-optimal policies for budget-constrained score maximization. Our model achieves state-of-the-art diagnosis accuracy with substantial cost savings (up to 85% reduction) across various clinical tasks.
Augmenting AI-Powered Clinician Decision Support Tools for Severe Infection through Dynamic Coupling of Novel Wearables and Electronic Medical Record Models Enhanced with Federated Learning Models
Imanuel Lerman, MD, MSc, Professor, Electrical and Computer Engineering, Anesthesiology, University of California, San Diego
Our group is developing an AI-powered clinician decision health care platform comprised of real-time ingestion of EHR data features aggregated in a federated learning architecture. Federated learning models dynamically couple to an AI-enabled wearable sensor that indicates early-stage infection (12 hours prior to standard-of-care). The dynamically coupled model will notify the clinician of critical change in patient infectious status allowing for expedited lifesaving therapeutics.
Coffee Break in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)10:05 am
Cognitive Automation to Improve Precision and Improve Clinical Care: Use Case Studies in Stroke Management
Can we leverage Artificial Intelligence (AI) to address clinical tasks that involve interpreting multimodal patient data and clinicians’ cognitive capabilities—or even beat the clinicians’ performance? We describe novel AI tools developed at Houston Methodist Hospital that address clinical challenges in triage, diagnosis, and treatment of stroke in emergency rooms and beyond.
Enjoy Lunch on Your Own11:25 am
Refreshment Break in the Exhibit Hall with Last Chance Poster Viewing1:00 pm
Jithesh Veetil, PhD, Senior Program Director, Digital Health & Technology, Medical Device Innovation Consortium
Advancing the AI in Diagnostics and Healthcare: Role of the Public-Private Partnership Model
Novel technologies including AI promise to revolutionize healthcare, from earlier diagnosis to better treatments and improved clinical care—to name just a few. However, some of the perpetual concerns are the scarcity of data and the uncertainty in the regulatory frameworks. In addition, many of the stakeholders in the fast-moving space are working in silos. This presentation will highlight a few concrete examples of how public-private partnerships such as MDIC are bringing together stakeholders across the ecosystem and delivering unique solutions to accelerate and adopt innovation in healthcare.
Unlocking the Potential of Digital Pathology and Artificial Intelligence (AI) through Regulatory Science
Industry and regulatory leaders will discuss recent advances in digital pathology and AI as well as the progress and hurdles in the quest to broadly implement digital pathology and AI/machine learning (ML). The impact of recent regulatory and legislative developments in digital pathology and AI tools in diagnostics will be highlighted as well as the work of the Pathology Innovation Collaborative Community (PIcc), a regulatory science initiative that aims to facilitate innovations in pathology.
Maryellen de Mars, PhD, Program Director, Clinical Diagnostics, Medical Device Innovation Consortium
Jochen Lennerz, MD, PhD, CSO, BostonGene
Keith Wharton, Jr, MD, PhD, Global Medical Affairs Leader - Pathology, Roche Diagnostics Solutions
Close of Conference3:15 pm
Conference Programs